Double-hit lymphoma (DHL) is an aggressive form of DLBCL, and it can be harder to treat than typical DLBCL. That said, there are treatment options available, and some people do respond well.
Because of its aggressive nature, doctors generally recommend more intensive treatment regimens rather than the standard R-CHOP chemo Show Full Answer
Double-hit lymphoma (DHL) is an aggressive form of DLBCL, and it can be harder to treat than typical DLBCL. That said, there are treatment options available, and some people do respond well.
Because of its aggressive nature, doctors generally recommend more intensive treatment regimens rather than the standard R-CHOP chemotherapy. Current approaches often combine multiple chemotherapy drugs alongside rituximab (Rituxan), which specifically targets the cancer cells. When DHL is diagnosed, it's often at an advanced stage, and it can sometimes be resistant to treatment or relapse after an initial response. However, there are several options available if that happens, including:
- More intensive chemotherapy combinations
- CAR T-cell therapy
- Bone marrow transplant
- Bispecific antibodies
- Clinical trials exploring newer therapies
A 2014 study found that 50% of people with DHL were still alive after two years, and 40% of those showed no signs of disease progression — which is encouraging given how aggressive DHL can be.
Talking openly with an oncologist about the latest treatment options is really important, as this is a fast-moving area with ongoing clinical trials that may offer access to newer therapies.
April 24
Join
Your Privacy Choices
